LEADER 04144nam 2200997z- 450 001 9910404091503321 005 20210211 010 $a3-03928-713-3 035 $a(CKB)4100000011302223 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/56130 035 $a(oapen)doab56130 035 $a(EXLCZ)994100000011302223 100 $a20202102d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPharmaceutical Crystals 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (148 p.) 311 08$a3-03928-712-5 330 $aThe crystalline state is the most commonly used essential solid active pharmaceutical ingredient (API). The characterization of pharmaceutical crystals encompasses many scientific disciplines, but the core is crystal structure analysis, which reveals the molecular structure of essential pharmaceutical compounds. Crystal structure analysis provides important structural information related to the API's wide range of physicochemical properties, such as solubility, stability, tablet performance, color, and hygroscopicity. This book entitled "Pharmaceutical Crystals"" focuses on the relationship between crystal structure and physicochemical properties. In particular, the new crystal structure of pharmaceutical compounds involving multi-component crystals, such as co-crystals, salts, and hydrates, and polymorph crystals are reported. Such crystal structures were investigated in the latest studies that combined morphology, spectroscopic, theoretical calculation, and thermal analysis with crystallographic study. This book highlights the importance of crystal structure information in many areas of pharmaceutical science and presents current trends in the structure-property study of pharmaceutical crystals. The Guest Editors of this book hope the readers enjoy a wide variety of recent studies on Pharmaceutical Crystals. 606 $aChemistry$2bicssc 610 $a1H-indole 610 $a3 610 $a4-b]indol-4-one 610 $a5-dihydro-4H-pyrimido[5 610 $aadefovir dipivoxil 610 $aBenzodioxole 610 $acarbamazepine 610 $acocrystal 610 $acocrystal formation 610 $acrystal habit 610 $acrystal structure 610 $aCrystal structure 610 $acrystal structure analysis 610 $adehydration 610 $aDFT 610 $aDFT study 610 $adicarboxylic acid 610 $adissolution 610 $afamotidine 610 $afamoxadone 610 $aHBV 610 $ahepatitis B 610 $aHirshfeld surface analysis 610 $aHOMO-LUMO 610 $ahydrate 610 $ahydrogen bond 610 $ahydrogen bonding 610 $ahydrogen-bond-acceptance ability 610 $ahygroscopicity 610 $aImidazole 610 $aliquid assisted grinding 610 $amalonic acid 610 $amelting diagram 610 $amolecular docking study 610 $an/a 610 $aNitrofurantoin-4-dimethylaminopyridine (NF-DMAP) salt 610 $aon-line monitoring 610 $aondansetron 610 $apharmaceutical cocrystal 610 $apharmaceutical crystals 610 $aphotostability 610 $aphysicochemical properties 610 $apolymorphs 610 $apyrimidin-4(3H)-one 610 $aRaman spectroscopy 610 $areactivity descriptors 610 $asaccharin 610 $asalt optimization 610 $aSemicarbazone 610 $asolubility 610 $asolution crystallization 610 $asolvent-mediated polymorphic transformation 610 $astructure determination from powder diffraction data 610 $asuccinic acid 610 $aticagrelor 615 7$aChemistry 700 $aUekusa$b Hidehiro$4auth$01297602 702 $aYonemochi$b Etsuo$4auth 906 $aBOOK 912 $a9910404091503321 996 $aPharmaceutical Crystals$93024601 997 $aUNINA